Crescent Grove Advisors LLC Sells 1,510 Shares of Johnson & Johnson (NYSE:JNJ)

Crescent Grove Advisors LLC trimmed its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 21.6% in the 1st quarter, HoldingsChannel reports. The fund owned 5,484 shares of the company’s stock after selling 1,510 shares during the quarter. Crescent Grove Advisors LLC’s holdings in Johnson & Johnson were worth $972,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Family CFO Inc bought a new position in shares of Johnson & Johnson in the 4th quarter worth $26,000. Steward Financial Group LLC purchased a new position in Johnson & Johnson during the 4th quarter worth $34,000. Joseph P. Lucia & Associates LLC purchased a new position in Johnson & Johnson during the 1st quarter worth $38,000. Advocacy Wealth Management Services LLC grew its stake in Johnson & Johnson by 41.4% during the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock worth $41,000 after buying an additional 67 shares during the last quarter. Finally, Gibson Wealth Advisors LLC purchased a new position in Johnson & Johnson during the 4th quarter worth $49,000. 68.78% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several research analyst reports. Morgan Stanley boosted their target price on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research note on Friday, July 8th. Credit Suisse Group boosted their target price on Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. The Goldman Sachs Group boosted their target price on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. Citigroup dropped their price target on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $171.11 on Friday. The stock has a market cap of $449.88 billion, a PE ratio of 24.91, a price-to-earnings-growth ratio of 3.32 and a beta of 0.59. The business has a 50-day simple moving average of $175.21 and a 200-day simple moving average of $174.55. The company has a quick ratio of 1.14, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.02. The business had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.48 EPS. On average, equities analysts expect that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be issued a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a yield of 2.64%. Johnson & Johnson’s payout ratio is 65.79%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.